ARL6IP6 Proteins, cDNA Clones Research Reagents

All ARL6IP6 reagents are produced in house and quality controlled, including 26 ARL6IP6 Gene, 1 ARL6IP6 Lysate, 1 ARL6IP6 Protein, 2 ARL6IP6 qPCR. All ARL6IP6 reagents are ready to use.

ARL6IP6 Protein (1)

    ARL6IP6 cDNA Clone (26)

    BC028741

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_022989.4

    クローニングベクター cDNA 製品

    In lentiviral vector

    ARL6IP6 Lysate (1)

      ARL6IP6 の背景知識

      It had been found that a homozygous truncating mutation in ARL6IP6 as the likely cause of a syndromic form of CMTC associated with major dysmorphism, developmental delay, transient ischemic attacks and cerebral vascular malformations. This gene was previously implicated by genome wide association study (GWAS) as a susceptibility locus to ischemic stroke in young adults. We identify ARL6IP6 as a novel candidate gene for a syndromic form of CMTC. This suggests that ischemic stroke or transient ischemic attacks (TIA) may represent, at least in some cases, the mild end of a phenotypic spectrum that has at its severe end autosomal recessive CMTC. This finding contributes to a growing appreciation of the continuum of Mendelian and common complex diseases.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.